Microbot Medical's (MBOT) "Buy" Rating Reiterated at HC Wainwright

Key Points

• HC Wainwright reiterated a "Buy" on Microbot Medical and set a $12.00 target, implying a potential upside of 410.64% from the prior close.
• The stock opened around $2.35 (down ~9.3%), with a market cap near $157.8 million and a 52‑week range of $1.60–$4.67.
• Microbot reported quarterly EPS of -$0.04, beating estimates of -$0.06, while analyst coverage is mixed and the consensus is a "Moderate Buy" with an average target of $7.50.

Microbot Medical (NASDAQ:MBOT - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $12.00 target price on the biotechnology company's stock. HC Wainwright's price objective points to a potential upside of 410.64% from the stock's previous close.

Several other research analysts also recently commented on the stock. B. Riley Financial initiated coverage on shares of Microbot Medical in a research report on Tuesday, February 10th. They set a "buy" rating for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Microbot Medical in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $7.50.

Microbot Medical Trading Down 9.3%

Shares of MBOT stock opened at $2.35 on Tuesday. The stock has a market cap of $157.83 million, a P/E ratio of -8.10 and a beta of 1.19. The stock has a 50 day simple moving average of $2.35 and a 200 day simple moving average of $2.32. Microbot Medical has a 1 year low of $1.60 and a 1 year high of $4.67.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last issued its quarterly earnings results on Sunday, March 22nd. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. Analysts forecast that Microbot Medical will post -0.71 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Beacon Capital Management LLC increased its holdings in shares of Microbot Medical by 37.5% during the third quarter. Beacon Capital Management LLC now owns 22,000 shares of the biotechnology company's stock worth $67,000 after buying an additional 6,000 shares in the last quarter. Cetera Investment Advisers increased its holdings in shares of Microbot Medical by 38.8% during the fourth quarter. Cetera Investment Advisers now owns 29,313 shares of the biotechnology company's stock worth $59,000 after buying an additional 8,201 shares in the last quarter. Cornerstone Advisory LLC acquired a new position in shares of Microbot Medical during the third quarter worth $30,000. Zacks Investment Management acquired a new position in shares of Microbot Medical during the third quarter worth $33,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Microbot Medical during the third quarter worth $37,000. 16.30% of the stock is currently owned by institutional investors and hedge funds.

About Microbot Medical

Microbot Medical Inc NASDAQ: MBOT is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.